Articles tagged with Chronic Viral Infections
Dr. Augusto Ochoa, Director of LSUHSC's Stanley S. Scott Cancer Center, has been awarded a $2.5 million NIH grant to develop new treatments for severe viral diseases, including herpes infections and cancers caused by viruses. The research aims to manipulate the immune system's response to these diseases.
Researchers at A*STAR have discovered a new personalized treatment strategy that utilizes a patient's own blood to treat chronic infections. By harnessing the power of monocytes, white blood cells can capture and utilize viruses to boost the immune response.
A study by researchers at the Perelman School of Medicine reveals how T-cell exhaustion occurs in chronic viral infections, with implications for novel therapies. The team found that two distinct classes of virus-specific CD8+ T cells work together to keep the infection in check, but their long-term pressure depletes progenitor pools.
A recent study reveals that hepatitis A virus (HAV) evades the innate immune response more effectively than hepatitis C virus (HCV), which causes chronic infections. The research provides critical insights into the nature of HCV's persistence and highlights the importance of understanding how the body responds to these viruses.
Researchers have discovered how a key viral gene helps viruses evade early detection by the immune system, providing new insights into chronic infection treatments. Dendritic cells, critical for immune response, are compromised by this gene, allowing viruses to establish chronic infections.
Researchers at Yerkes National Primate Research Center and Emory Vaccine Center found that trapping white blood cells in lymph nodes can help mice fight chronic viral infections. FTY720, an experimental drug, prevents white blood cells from leaving lymph nodes, improving immune response against the virus.
A team of researchers has found that trapping white blood cells in the lymph nodes can help mice overcome a chronic viral infection. Experimental drug FTY720, also known as fingolimod, prevents white blood cells from responding to the virus by desensitizing them to sphingosine-1-phosphate.
Scientists at The Wistar Institute found that CD8 T cells generated to fight chronic infections operate under a different maintenance scheme than those in acute infections. These cells have a rapid turnover and are dependent on the virus for their continuation, which could be manipulated to design new therapeutic options.
A recent study found that antibiotics are prescribed for approximately 82% of acute and chronic sinus infections, despite viruses being the most frequent cause. This overprescription has significant concerns, including drug resistance and virulent bacteria, as well as increased healthcare costs.
Researchers identify genetic changes in hepatitis C virus that evade immune system, leading to chronic infections. The findings suggest a 'consensus sequence' could serve as basis for effective vaccines against both acute and chronic infections.
Researchers discovered that a new class of protease inhibitors can prevent the hepatitis C virus from blocking the innate immune response, restoring it in human cells. This finding suggests that these drugs will have dual efficacy and could become an important addition to existing treatments for hepatitis C.
A new study has established genetic associations in hepatitis C, finding correlations between the CD4 and IL-1B genes and disease activity. The research suggests a possible role of intrahepatic CD4 T cells in hepatic injury and immune response to HCV infection.
A study led by the National Institutes of Health (NIH) has identified key changes in surface proteins of the hepatitis C virus (HCV) that enable it to evade the immune system. The research found that these changes occur early in the infection process and can determine whether a person will develop chronic or acute HCV disease.
Hepatitis C virus (HCV) can mimic one of its molecular targets, blocking interferon's ability to kill viruses. This discovery may lead to the development of new therapies by targeting the E2 protein sequence that interferes with PKR phosphorylation.
Researchers found that most hepatitis B virus infections in adult humans are uncomplicated and do not result in large-scale destruction of infected liver cells. A new noncytolytic process targets the virus' ability to reproduce, leaving the liver relatively unscathed.
Researchers at TSRI demonstrate that the immune system can cure viral infections without destroying infected cells. Nondestructive antiviral mechanisms triggered by inflammatory cytokines contribute to viral clearance, preserving organ function.
Researchers at Chiron Corporation have identified a protein molecule (CD81) that binds to the hepatitis C virus (HCV), providing clues on how the virus infects human cells. This discovery has significant implications for the development of new vaccines and therapeutics to prevent and treat chronic HCV infection.